Biomolecular markers of cancer-associated thromboembolism - Wikidata - wikimedia - TriplyDB

Biomolecular markers of cancer-associated thromboembolism

Biomolecular markers of cancer-associated thromboembolism

http://www.wikidata.org/entity/Q26865716

about

The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.Venous thrombosis and cancer: from mouse models to clinical trials.Coagulation Biomarkers in Healthy Chinese-Origin Rhesus Macaques (Macaca mulatta)Cancer and Thrombosis: The Platelet Perspective.The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.Synthesis, characterization, and biological studies of diosgenyl analogs.Fibrinogen and D-dimer levels in prostate cancer: Preliminary results A pilot study on the applicability of thromboelastometry in detecting brain tumour-induced hypercoagulation.Role of P-selectin in thromboembolic events in patients with cancer.

P2860

Q34748167-5E6A6D49-40D6-4363-A381-2ED51468D5CF Q36636558-5FC5521F-B4C4-401F-90D9-4143D50510B0 Q36897415-AE15CB95-3672-44D7-A132-420C18202539 Q37558436-6FC95A02-0D0F-44E5-AAD5-FB9C17B2DE99 Q38747529-398B7B79-F1DE-4A85-8C21-BB02C246DFB1 Q38759784-D45FB020-DE3F-48B7-9D13-6F90DD237839 Q41345857-C450FFEC-5398-48B4-A736-423814B5253E Q47313341-FA50181B-1EE7-483C-A61B-30BAC68EEE07 Q50224260-DF2DDC22-CE28-4A35-8AA2-E904320E9055

P2860

Biomolecular markers of cancer-associated thromboembolism

http://www.wikidata.org/entity/Q26865716

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Biomolecular markers of cancer-associated thromboembolism

@ast

Biomolecular markers of cancer-associated thromboembolism

@en

Biomolecular markers of cancer-associated thromboembolism

@nl

type

label

Biomolecular markers of cancer-associated thromboembolism

@ast

Biomolecular markers of cancer-associated thromboembolism

@en

Biomolecular markers of cancer-associated thromboembolism

@nl

prefLabel

Biomolecular markers of cancer-associated thromboembolism

@ast

Biomolecular markers of cancer-associated thromboembolism

@en

Biomolecular markers of cancer-associated thromboembolism

@nl

P1433

Q26865716-08B8BCD6-CB23-4962-BDB2-C86D0B9F647F

P1476

Q26865716-A02E0984-BAE4-43FF-A282-E774EE34283F

P2093

Q26865716-2825B781-389E-4B38-9B8B-9CDE2FE64726

Q26865716-43E1E06F-C2E9-483A-8936-929CED537C45

Q26865716-C5158633-CEFE-484F-91DB-F7B38F0E94D6

P2860

Q26865716-00A29E26-4A25-49B1-907C-F8321DEB435A

Q26865716-01E8904B-A398-4F91-90D0-86CEDBFB3147

Q26865716-05CD4D36-54F0-434E-8DC9-6708B105117E

Q26865716-0769EEEC-D00D-44D7-9C19-CDAB38CEE667

Q26865716-0B18AB0C-DF47-4DA9-A35B-ED7FD6C573DE

Q26865716-0B65ECBE-CE62-458F-B8C3-DC8335B9BAA8

Q26865716-10873FF9-2963-4A75-9270-C209E36AD090

Q26865716-10C59D70-2D1B-4AFB-A045-BEB67934B640

Q26865716-12C760FE-B166-4D49-A2B3-8556EC28DF65

Q26865716-1C63E310-67C2-4CE7-B618-909F90C160BB

P304

Q26865716-71BCF271-799D-494E-B483-7A73B88AF0A0

P31

Q26865716-4D6D7E12-0996-474A-BE22-B7FB1FC7E56A

P356

Q26865716-A5C3DA08-EE33-427F-AF7A-1102E1C1B7AE

P407

Q26865716-85E70DD9-33CA-4466-A107-33B4A26B73ED

P433

Q26865716-3C2A8D92-281A-44EB-82DD-F066235CEFC7

P478

Q26865716-1F724355-B330-449F-965D-D02B37836D69

P577

Q26865716-7E19AB90-3495-41A0-A3A8-244135DF2E0C

P698

Q26865716-CDD72B2B-CB80-454D-8D98-4EF2F1EE8684

P921

Q26865716-37081C0F-92F4-4642-A9E1-992EA999E4A8

P932

Q26865716-60D7C5BB-A082-4F6F-82FC-B2024060F386

P356

J.CRITREVONC.2013.02.008

P1433

Critical Reviews in Oncology Hematology

P1476

Biomolecular markers of cancer-associated thromboembolism

@en

P2093

Diana L. Hanna

http://www.w3.org/2001/XMLSchema#string

Richard H. White

http://www.w3.org/2001/XMLSchema#string

Ted Wun

http://www.w3.org/2001/XMLSchema#string

P2860

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo

Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein

The hypercoagulable state of malignancy: pathogenesis and current debate

P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis

Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

The thrombophilic state induced by therapeutic agents in the cancer patient.

Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer.

Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.

P304

19-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CRITREVONC.2013.02.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23522921

http://www.w3.org/2001/XMLSchema#string

P921

thromboembolism

P932

3742654

http://www.w3.org/2001/XMLSchema#string